Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor class drugs

18 results
Zydus Lifesciences Limited

Delstrigo (doravirine, lamivudine, and tenofovir disoproxil fumarate)

(doravirine, lamivudine, and tenofovir disoproxil fumarate)
Merck Sharp & Dohme LLC
Usage: DELSTRIGO® is indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg, either as a complete regimen for those with no prior antiretroviral treatment history or to replace the current regimen in patients who are virologically suppressed.

Dovato (dolutegravir sodium and lamivudine)

(dolutegravir sodium and lamivudine)
ViiV Healthcare Company
Usage: DOVATO is indicated for the treatment of HIV-1 infection in adults and adolescents (ages 12 and older, weighing at least 25 kg) with no prior antiretroviral therapy or to replace the current regimen in those who are virologically suppressed without resistance concerns.
Cipla USA Inc.
Usage: Efavirenz, Emtricitabine, and Tenofovir disoproxil fumarate are indicated for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg, either as a complete regimen or in combination with other antiretroviral agents.
Aurobindo Pharma Limited
Usage: Emtricitabine capsules are indicated for the treatment of HIV-1 infection, to be used in combination with other antiretroviral medications.
Cipla USA Inc.
Usage: Emtricitabine is indicated for the treatment of HIV-1 infection, used in combination with other antiretroviral agents.
American Health Packaging
Usage: Emtricitabine and tenofovir disoproxil fumarate are indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents in adults and children over 17 kg, and for pre-exposure prophylaxis (PrEP) in at-risk adolescents and adults weighing at least 35 kg.
Amneal Pharmaceuticals NY LLC
Usage: Emtricitabine and tenofovir disoproxil fumarate tablets are indicated for the treatment of HIV-1 infection in adults and pediatric patients (≥17 kg) and for pre-exposure prophylaxis (PrEP) in at-risk adolescents and adults (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection.
Zydus Lifesciences Limited
Rising Pharma Holdings, Inc.
Usage: Lamivudine oral solution is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents. It is specifically dosed for HIV-1 and is not indicated for hepatitis B virus (HBV) treatment.